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The MS4A gene family in humans includes CD20 and at least 15 other genes. CD20
exists as homo-oligomers in the plasma membrane, however different MS4A proteins
expressed in the same cell may hetero-oligomerize. Given the importance of CD20 in B-
cell function and as a therapeutic target, we sought to explore the potential for CD20
hetero-oligomerization with other MS4A proteins. We investigated expression in primary
human B-cells of the four MS4A genes previously shown to be expressed in human B-cell
lines (MS4A4A, MS4A6A, MS4A7, MS4A8B), as well as two genes comprising the closely
relatedTMEM176 gene family, with a view to identifying candidates for future investigation
at the protein level. TMEM176A and TMEM176B transcripts were either not detected, or
were detected at relatively low levels in a minority of donor B-cell samples. MS4A4A and
MS4A8B transcripts were not detected in any normal B-cell sample. MS4A6A and MS4A7
transcripts were detected at low levels in most samples, however the corresponding pro-
teins were not at the plasma membrane when expressed as GFP conjugates in BJAB cells.
We also examined expression of these genes in chronic lymphocytic leukemia (CLL), and
found that it was similar to normal B-cells with two exceptions. First, whereas MS4A4A
expression was undetected in normal B-cells, it was expressed in 1/14 CLL samples. Sec-
ond, compared to expression levels in normal B-cells, MS4A6A transcripts were elevated in
4/14 CLL samples. In summary, none of the MS4A/TMEM176 genes tested was expressed
at high levels in normal or in most CLL B-cells. MS4A6A and MS4A7 were expressed at
low levels in most B-cell samples, however the corresponding proteins may not be posi-
tioned at the plasma membrane. Altogether, these data suggest that CD20 normally does
not form hetero-oligomers with other MS4A proteins and that there are unlikely to be other
MS4A proteins in CLL that might provide useful alternate therapeutic targets.
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INTRODUCTION
MS4A is a family of tetraspanning membrane proteins, most of
which remain uncharacterized (1, 2). Phylogenetic analysis indi-
cated that the genes encoding these proteins first appeared and
expanded in early vertebrates, with rapid diversification such that
homologs of some of the human MS4A genes are not found in the
mouse and vice versa (3). The founding member of this family,
MS4A1 (CD20), is expressed at high levels only in B-lymphocytes,
is associated with the B-cell antigen receptor (BCR) (4), functions
in BCR-activated calcium influx (5), and is required for optimal
humoral immunity (6). Expression of CD20 first occurs during the
pre-B stage of development and is lost upon terminal differentia-
tion to plasma cells. CD20 is also expressed at high levels in B-cell
lymphomas, and is an effective target for therapeutic depletion of
pathogenic B-cells in various disease settings (7–9). Rituximab and
other CD20-directed antibody therapeutics bind to epitopes on
one or both of the two small extracellular loops between the trans-
membrane spanning regions (10–13). The short length of these
loops brings bound antibodies close to the plasma membrane, a
property that is likely to contribute to the efficacy of CD20 as a tar-
get (9). Antibody-mediated stabilization of CD20 in lipid rafts (14,
15) appears to allow enhanced complement activation (16), and
the slow rate of internalization of antibody-bound CD20 allows
prolonged display of Fc regions to Fc receptor-bearing effector
cells (17–19). Some or all of these factors are likely to be shared by
other MS4A proteins, which could thus be a source of potentially
novel immunotherapeutic targets.
CD20 exists as homo-oligomers in the plasma membrane (4,
20), however it has been suggested that different MS4A pro-
teins expressed in the same cell may hetero-oligomerize with one
another. Indeed, hetero-oligomerization of murine MS4a4B and
MS4a6B has been reported (21), and unusual MS4A genes with
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fused repeating MS4A sequences occur in some species (3), sug-
gesting that hetero-oligomerization may be a general feature of
MS4A proteins. Given the importance of human CD20 to BCR
signaling, humoral immunity, and immunotherapeutic depletion
of B-cells, and the potential for other MS4A proteins to hetero-
oligomerize with CD20, we sought to identify non-CD20 MS4A
genes expressed in primary human B-cells. Most of the known
MS4A genes have expression that is restricted to other tissues, par-
ticularly myeloid-lineage cells, testes, lung, and intestinal tissues;
however, MS4A4A, MS4A6A, MS4A7, and MS4A8B were reported
to be expressed in human B-cell lines (2). We investigated the
quantitative expression of these 4 MS4A genes, as well as two
genes comprising the closely related TMEM176 gene family (3),
in human blood and tonsil B-cells with a view to identifying can-
didates for future investigation at the protein level. A secondary
goal was to identify MS4A proteins that might provide alternate
therapeutic targets for chronic lymphocytic leukemia (CLL), a B-
cell malignancy in which CD20 is expressed at much lower levels
than in B-cell lymphomas (22–24). We therefore also investigated
expression of MS4A and TMEM176 genes in a group of untreated
CLL patients.
MATERIALS AND METHODS
CELL ISOLATION
All samples in this study were obtained by approval of the Con-
joint Health Research Ethics Board at the University of Calgary.
Blood samples from healthy volunteer donors were obtained from
laboratory personnel in the Immunology Research Group, Univer-
sity of Calgary. Tonsils were obtained from patients undergoing
tonsillectomy at the Alberta Children’s Hospital. Whole blood
from patients with CLL was obtained anonymously as leftover
samples from the Flow Cytometry Laboratory of Calgary Labora-
tory Services at Foothills Medical Center; only samples with dim
CD20 expression and ≥96% CD5+ B-cells were included in the
study. All samples were processed within 24 h of collection. B-cells
were purified from whole blood using the RosetteSep™ Human B-
cell Enrichment Cocktail (StemCell Technologies, Vancouver, BC,
Canada) and from tonsils using a modified RosetteSep™ method
(25). CD5+ B-cells were prepared from normal blood B-cells using
the EasySep Positive Selection kit (StemCell Technologies) with
PE-conjugated anti-CD5 (BioLegend, Mississauga, ON, Canada).
CD27 positive selection was achieved using CD27-PE with the
EasySep PE magnetic selection kit. A minimum of 105 highly puri-
fied cells was collected for each population. T cells were purified
from whole blood using the Pan T Cell Isolation Kit II (Miltenyi
Biotec, Auburn, CA, USA).
RNA ISOLATION AND REAL-TIME PCR
Total RNA from blood and tonsil tissue was extracted using Tri-
zol (Invitrogen, Burlington, ON, Canada). RNA from a variety
of human tissues was purchased from Clontech, Mountain View,
CA. 1µg of total RNA was converted to cDNA using SuperScript
III Reverse Transcriptase (Invitrogen, Burlington, ON, Canada)
and oligo dT primers in a volume of 20µl. The cDNA sam-
ple was diluted to 100 and 1µl of this was used as template
for quantitative real-time PCR (qPCR) using SybrGreen (Applied
Biosystems, Streetsville, ON, Canada), the primer sets shown
in Table 1, and the ABI 7000 machine (Applied Biosystems)
in the 96-well format. Reactions were performed in duplicate
under the following conditions: 95 °C for 10 min followed by
40 cycles of 60 °C for 1 min and 95 °C for 15 s. Each run was
concluded with a melting curve analysis to verify the specificity
of the PCR product. Amplification of specific products was fur-
ther validated during PCR optimization by gel purification and
sequencing. Amplification efficiencies, calculated using 10-fold
dilutions (10−1 to 10−5) of cDNA prepared from tonsil B-cell
RNA, were close to 2.0 in every case (Table 1). Data were nor-
malized to an endogenous control, ACTB (β-actin). mRNA levels
in each sample were thus expressed as the difference between
threshold values (∆CT) for the gene transcript of interest and
ACTB, using the equation Ratio = (Etarget)∆CPtarget(control −
sample)/(Eref)
∆CPref(control− sample) (26).
cDNA CONSTRUCTS AND TRANSFECTIONS
The human MS4A4A, MS4A6A, MS4A7, and MS4A8B coding
sequences were cloned and inserted into the multicloning site
(MCS) of the pEGFP-C1 vector (Clontech, Mountain View, CA,
USA). BJAB cells were electroporated at 340 V and 950µF (Gene
Pulser II, Bio-Rad, Hercules, CA, USA) with 20µg of cDNA. GFP-
positive cell lines were generated in 1 mg/ml Geneticin (Life Tech-
nologies). BJAB cells stably expressing GFP-CD20 were previously
established (15).
IMMUNOFLUORESCENCE MICROSCOPY
Cells were incubated with antibodies either before or after fixa-
tion in 4% paraformaldehyde (PFA, Electron Microscopy Sciences,
Hatfield, PA, USA) at room temperature for 15 min. Antibodies
against EEA1, golgin 95, golgin 97, and giantin were provided by
Dr. Marvin Fritzler (University of Calgary, AB, Canada). CD20
mAb 2H7 was provided by Dr. J. Ledbetter (Bristol-Myers Squibb,
Seattle, WA, USA). Cy3-conjugated F(ab′)2 goat anti-mouse IgG
was purchased from Jackson ImmunoResearch Laboratories Inc.
(West Grove, PA, USA). Nuclei were stained with 4′-6-Diamidino-
2-phenylindole (DAPI, Sigma). Fluorescence imaging was done
with a Leica DM RXA microscope (Rockleigh, NJ, USA) attached
to a 14-bit cooled CCD camera (Princeton Instruments, Mon-
mouth Junction, NJ, USA). Digital deconvolution was performed
using the nearest neighbor algorithm, Microtome for Windows
(Vaytek, Fairfield, IA, USA).
RESULTS
The MS4A4A, MS4A6A, MS4A7, and MS4A8B genes were selected
for analysis in this study on the basis of evidence that they are
expressed in B-cell lines (2). MS4A genes with expression known
to be limited to myeloid-lineage cells or non-hematopoietic tissues
were excluded. MS4A1 (CD20), which is expressed at high levels
in mature B-cells, was included for comparison. In addition, we
examined expression of the MS4A-related genes, TMEM176A and
TMEM176B, which have not previously been assessed in human
B-cells. The levels of expression were assessed using quantita-
tive RT-PCR (qPCR), with validation of the primer sets done
by confirming the expected sizes and sequences of the amplified
products. Amplification of each gene was compared to that of
ACTB (β-actin) and shown on the y-axes in Figures 1 and 2 as
Relative mRNA.
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Table 1 | Human MS4A/TMEM176 qPCR primer sequences and properties.
Primer name Accession number Sequence Melting temp. AE1
qhMS4A1F NM_152866.2 CAC CCA TCT GTG TGA CTG TGT G 68 1.98
qhMS4A1R AGT TTT TCT CCG TTG CTG CC 60
qhMS4A4AF NM_148975.2 TGG CTG TCA TAC ATT CAC ATC TG 60 2.04
qhMS4A4AR CCA TAC ACA TCA TTG TTA TTC CCA 60
qhMS4A6AF NM_152852.2 CAC GCA GAA ATC AAA GTT ATT G 60 1.98
qhMS4A6AR TGG GTA AGC AGA GTT CAA CAG TG 68
qhMS4A7F NM_021201.4 CAC CAA AGG GCA TCA CTA TCC 64 1.92
qhMS4A7R GAA ATC AAC AGG CAA CAC AGG 62
qhMS4A8BF NM_031457.1 GAT CTC TCT CCG TGG CAG C 60 2.19
qhMS4A8BR TGA CGA TGT TCA AGC CCA AAC 60
qhTMEM176AF NM_018487.2 GAG TCC AGA AGA AGT CAG AAG GC 70 2.06
qhTMEM176AR AAG CAG CAG AAT CCA GAC ACC 64
qhTMEM176BF NM_014020.3 GGC AGA AGG AGG AGT GTA GAG C 70 1.98
qhTMEM176BR CAG GAA CAG GGC ACG GAT T 60
qhB-ACTINR NM_001101.3 GTG TTG GCG TAC AGG TCT TTG 64 2.01
qhB-ACTINF CAC TCT TCC AGC CTT CCT TCC 66
1Amplification efficiency.
FIGURE 1 |MS4A/TMEM176 mRNA levels in non-hematopoietic human
tissues. cDNA was prepared from tissue RNA samples in the human total
RNA master panel II (Clontech). Quantitative PCR was performed to amplify
MS4A1, MS4A4A, MS4A6A, MS4A7, MS4A8B, TMEM176A, TMEM176B, and
ACTB cDNA using primer sets with equivalent amplification efficiencies
(Table 1). Vertical axes show mRNA levels relative to ACTB.
We first examined the expression of the MS4A and TMEM176
genes in non-hematopoietic tissues (Figure 1). Detection of
MS4A1 (CD20) transcripts in the lung, trachea, thyroid, and
uterus is probably indicative of blood contamination or infiltra-
tion of these tissues. Among non-hematopoietic tissues, MS4A4A
detection was limited to the lung. Considering that MS4A1
(CD20) transcripts were also amplified from the lung, MS4A4A
may be expressed on a hematopoietic cell type in that tis-
sue. MS4A8B was expressed most highly in the lung and tra-
chea, consistent with a previous report (27), and was also
expressed in a few other tissues but with a more restricted pro-
file than the remaining genes, MS4A6A, MS4A7, TMEM176A, and
TMEM176B, which were detected broadly in non-hematopoietic
tissues (Figure 1).
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FIGURE 2 |MS4A/TMEM176 mRNA levels in normal and CLL B-cells.
cDNA was prepared from freshly isolated normal B-cell samples and CLL
B-cell samples. Quantitative PCR was performed to amplify MS4A1,
MS4A4A, MS4A6A, MS4A7, MS4A8B, TMEM176A, TMEM176B, and ACTB
cDNA as in Figure 1. Vertical axes show mRNA levels relative to ACTB. Each
data point represents one donor or patient sample. (A) peripheral blood (PB)
B-cells isolated from seven healthy donors, B-cells isolated from tonsillar
tissue from seven patients, CD5+ B-cells sorted from five donor blood
samples, CD27+ B-cells sorted from three donor blood samples, and (B) 14
CLL B-cell samples. Means and SEM are indicated by the horizontal bars. (C)
Quantitative PCR data from the 14 blood and tonsil B-cell samples were
compared with data from the 14 CLL B-cell samples, with means and SEM
shown. Data were analyzed by Mann–Whitney U and there was no statistical
significance between the groups (p>0.05).
We then examined expression of the MS4A4A and TMEM176
genes in B-cells isolated from multiple donor samples of periph-
eral blood and tonsil tissues. As expected, MS4A1 (CD20)
transcripts were always detected at high levels (Figure 2A).
Surprisingly, however, we detected only relatively low levels of
transcripts for any of the six new MS4A/TMEM176 genes in
either tonsil or peripheral blood B-cells. Indeed, MS4A4A and
MS4A8B transcripts were not detected in any sample (Figure 2A).
MS4A6A and MS4A7 transcripts were detected in most B-cell
samples but at two to four orders of magnitude lower than
MS4A1 (CD20). TMEM176A and TMEM176B transcripts were
found in a minority of blood and tonsil B-cell samples. The
expression of MS4A and TMEM176 genes in CD5+ blood B-
cells and CD27+ (memory) blood B-cells was examined with
similar findings: no detection of MS4A4A or MS4A8B, and
low or no detection of transcripts from the remaining genes
(Figure 2A).
Data were obtained for 14 blood samples obtained from CLL
patients (Table 2) and tested similarly for the expression of the
MS4A4A and TMEM176 genes (Figure 2B). MS4A1 (CD20)
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Table 2 | Chronic lymphocytic leukemia patients.
Age Gender Months since
diagnosis1
WBC
count
RAI
stage
Prior
treatment
01 55 F 1 9.5 1 No
02 62 M 0 8 1 No
03 71 F 0 5 0 No
04 58 F 1 13 0 No
05 69 M 0 5 0 No
06 78 F 0 na2 na2 No
07 66 M 0 12 2 No
08 47 F 50 24 0 No
09 83 F 0 79 0 No
10 79 M 0 12 1 No
11 49 F 0 10 0 No
12 54 M 0 33 0 No
13 71 M 0 20 0 No
14 58 F 0 na2 1 No
Data obtained from Calgary Laboratory Services with ethical approval.
1Months between diagnosis and time of testing; 2na, not available.
transcripts were detected at high levels in every sample, as expected
(24). MS4A4A expression,which was undetected in normal B-cells,
was detected in a single sample. Notably, MS4A6A transcripts were
detected at higher levels in 4/14 of CLL samples than in all but
one of the 14 normal blood or tonsil B-cell samples, the single
exception being one of the blood CD27+ samples. However, the
differences in MS4A6A expression between CLL and normal B-
cells were not statistically significant (Figure 2C). MS4A8B was
not detected in any CLL sample. Expression of MS4A7 and the
TMEM176 genes was either low or undetected in CLL samples, as
it was in normal B-cells.
Statistical analysis confirmed that the levels of all MS4A and
TMEM176 transcripts in CLL were not different than levels found
in normal B-cells (Figure 2C).
The data obtained from normal primary B-cells indicated some
expression of MS4A6A and MS4A7 in the majority of the sam-
ples tested (Figure 2A). In order to assess the potential for the
corresponding MS4A proteins to hetero-oligomerize with CD20,
we expressed them as GFP fusion proteins in the human BJAB
cell line and examined their subcellular localization by fluores-
cence microscopy. GFP-tagged MS4A4A, MS4A8B, and CD20 were
expressed for comparison. Cells were fixed and nuclei stained
with DAPI. GFP-MS4A4A and GFP-MS4A8B, like GFP-CD20,
appeared to be expressed at the plasma membrane (Figure 3A)
and this was confirmed by visualizing the plasma membrane
using anti-CD20 (Figure 3C). In contrast, GFP-MS4A6A and
GFP-MS4A7 were localized intracellularly in the perinuclear space
(Figure 3A). To characterize the intracellular compartment, we
stained early endosomes, cis-Golgi, cis/medial Golgi, and trans-
Golgi compartments using antibodies detecting EEA1, golgin
97, golgin 95, and giantin, respectively. Both GFP-MS4A6A and
GFP-MS4A7 co-localized with giantin, indicating that they were
concentrated in the trans-Golgi complex (Figure 3B); no colocal-
ization with EEA1, golgin 97, or golgin 95 was observed (data not
shown).
FIGURE 3 | Intracellular localization of GFP-tagged MS4A6A and
MS4A7. BJAB cell lines were derived that express GFP-tagged MS4A4A,
MS4A6A, MS4A7, MS4A8B, and CD20. (A) Immunofluorescence images
are of individual cells representative of >100 cells observed in at least two
independent experiments for each cell line. Cells were fixed and nuclei
stained with DAPI. In the case of GFP-MS4A6A and GFP-MS4A7 the cells
were counterstained with mouse anti-human CD20 (2H7) and
Cy3-conjugated F(ab′)2 anti-mouse IgG to delineate the plasma membrane.
(B) Cells expressing GFP-MS4A6A or GFP-MS4A7 were fixed,
permeabilized, and stained with rabbit anti-giantin and Cy3-conjugated
anti-rabbit IgG to mark the trans-Golgi. Control experiments with
non-specific primary antibody confirmed the specificity of the fluorescent
signals obtained. Single-labeled control samples were imaged separately to
confirm negligible bleed-through of fluorophores to the other channel.
Nuclei were stained with DAPI. Results are representative of >100 cells
observed in at least two independent experiments. (C) Cells expressing
GFP-MS4A4A or GFP-MS4A8B were stained for CD20 as in (A).
DISCUSSION
This report describes the results of our investigation into the
expression of MS4A4A, MS4A6A, MS4A7, MS4A8B, and both
of the MS4A-related TMEM176 genes in normal B-cells and in
CLL. Unlike MS4A1 (CD20), which is consistently and highly
expressed in both normal and CLL B-cells at the mRNA level,
the other MS4A/TMEM176 genes tested were either not expressed
or expressed at relatively low and/or variable levels. MS4A4A and
MS4A8B genes were not expressed in normal blood or tonsil-
lar B-cells; this was a surprising result given a previous report of
their expression in B-cell lines (2), however, antibodies generated
against the corresponding proteins confirmed that MS4A4A and
MS4A8B are not expressed in mature human B-cells (not shown).
MS4A6A and MS4A7 transcripts were detected at low levels,
generally 200–400 times lower than MS4A1 (CD20). A recent
global analysis of RNA and protein levels showed that they are
significantly correlated in ∼40% of comparisons, higher than
previous estimates but clearly not absolute (28). Although the
overall correlation is relatively poor, unstable mRNAs tend not
to generate stable proteins except in restricted categories of pro-
teins such as those regulating RNA processing (28). Thus, it is
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unlikely that very low levels of mRNAs would generate high levels
of membrane proteins. We could not examine endogenous MS4A6
and MS4A7 as reliable antibodies were not available, however we
found that neither of these proteins localized to the plasma mem-
brane when expressed as GFP fusion proteins in a human B-cell
line. This is unlikely to be an artifact of GFP fusion as a sim-
ilarly constructed GFP-CD20 protein was properly localized to
the plasma membrane, as were GFP-MS4A4A and GFP-MS4A8B.
Known intracellular localization of MS4A3 (HTm4) provides a
precedent for intracellular localization of some other MS4A pro-
teins (29). It is possible that MS4A6A and/or MS4A7 are mobilized
to the plasma membrane under certain conditions, however, our
results suggest that neither MS4A6A or MS4A7 is found in suf-
ficient abundance or in the right subcellular compartment to
normally form hetero-oligomers with CD20 or to be considered
as an alternate therapeutic target for B-cell depletion.
TMEM176A and TMEM176B transcripts were undetected or
detected at only trace levels in most samples of normal blood
or tonsillar B-cells. From this it is clear that neither correspond-
ing protein is normally expressed in all mature human B-cells,
although expression could be upregulated under certain condi-
tions. Similar to MS4A6A and MS4A7, tissue expression was broad
for both TMEM176 genes suggesting generalized rather than cell-
type specific functions, and negating their potential utility as
therapeutic targets.
The expression profiles of the tested MS4A and TMEM176
genes in CLL were generally similar to that in normal B-cells,
however there were a few CLL samples in which expression levels
of one of the MS4A genes was unusually high. MS4A4A, which
was never detected in blood or tonsil B-cells, was expressed at a
high level in one CLL sample. This sample was from a patient who
presented with RAI stage II CLL at the time of diagnosis when the
sample was collected (Table 2), however studies on much larger,
defined patient populations would need to be performed to deter-
mine the significance, if any, of this observation. MS4A6A was
more highly expressed in about 1/3 of CLL samples than in any
of the normal B-cell samples, but this difference did not reach
statistical significance (Figure 2C). Our study was not designed
to test the potential correlation of differential MS4A/TMEM176
gene expression with clinical indicators of prognosis and no con-
clusions about the significance of these observations can be made
at this time. However, testing the protein expression of MS4A4A
and MS4A6A in a large cohort of defined CLL samples would be an
important direction when antibodies suitable for flow cytometry
become available.
In conclusion, we searched for and did not find evidence for
MS4A4A, MS4A6A, MS4A7, MS4A8B, or TMEM176 transcripts
likely to generate proteins in sufficient quantity to form hetero-
oligomers with the abundant CD20 molecules expressed in all
normal mature B-cells. MS4A4A and MS4A8B were not detected.
MS4A6A and MS4A7 transcripts were detected in most normal
B samples but at very low levels and the corresponding proteins
are probably not normally expressed at the plasma membrane.
TMEM176A and TMEM176B transcripts were only detected in a
minority of B-cell samples. Available data for other MS4A genes
shows expression restricted to myeloid-lineage cells, testis, lung,
and intestinal tissues. Therefore, in the absence of evidence of other
MS4A proteins co-expressed with CD20 at the plasma membrane,
it is most likely that CD20 normally exists in homo-oligomeric
form and that alternate therapeutic targets for B-cells are unlikely
to be found in the MS4A family. Novel targets are more likely to be
found among members of the unrelated but structurally similar
tetraspanin superfamily (30). Although broad tissue expression of
tetraspanin proteins such as CD9 and CD81 limits their poten-
tial in this regard, high expression of CD37 in B-cells makes it a
promising target for CLL and other B-cell cancers (31–34).
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